Which three groups of people are not suitable for taking Cabergoline and the potential risks

Cabergoline (Cabergoline) is a dopamine receptor agonist mainly used for the treatment of hyperprolactinemia, pituitary prolactinoma, and in some cases for the adjuvant treatment of Parkinson's disease. This drug works by inhibiting prolactin secretion and regulating pituitary function. However, because cabergoline has certain effects on the dopamine system and cardiovascular system, some people are at higher risk when using this drug, so they are not suitable for taking it. A comprehensive health assessment should be conducted before using this medicine to avoid serious adverse reactions.

Cabergoline should not be used in patients with valvular heart disease or severe cardiovascular disease. Studies have found that long-term use of the drug may be related to heart valve fibrosis and valve regurgitation, especially those with high doses or long-term treatment. Cabergoline may cause heart valve thickening by stimulating 5-HT2B receptors. Therefore, patients with existing heart valve disease or cardiac dysfunction may aggravate their condition after use. Clinically, it is recommended that patients undergo cardiac ultrasound examination before taking medication and review it regularly during treatment. Once heart valve abnormalities are found, medication should be discontinued immediately.

Cabergoline is not recommended for patients with a history of mental illness, such as depression or schizophrenia. By acting on central dopamine receptors, this drug may cause side effects such as mental excitement, hallucinations, and impulsive behavior. Some patients may even develop behavioral problems such as compulsive gambling, compulsive shopping, or heightened sex drive, especially if they have a mental illness or use other dopamine medications. Therefore, for those who are prone to psychotic symptoms or have a past medical history, doctors usually carefully assess the risks and choose alternative drugs or use them under strict monitoring.

Cabergoline is also not suitable for use in patients with severe hepatic impairment. The drug is mainly metabolized in the liver. If liver function is abnormal, it will cause delayed drug clearance, thereby increasing blood concentration and increasing the risk of adverse reactions, such as hypotension, nausea, dizziness, and gastrointestinal discomfort. For patients with mild to moderate liver function impairment, doctors may consider reducing the dosage or extending the dosing interval, and closely monitoring liver function indicators. Overall, although cabergoline has significant therapeutic effects, it should be strictly prohibited or used with caution in patients with heart disease, mental disorders, and liver dysfunction to ensure the safety and effectiveness of the treatment.

Reference materials:https://www.drugs.com/